Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Wanbang Biopharma Adds Animal Rights to Agreement for Diabetes Therapy

publication date: Nov 23, 2022

Xuzhou Wanbang Biopharma, a Fosun Pharma subsidiary, added animal rights to its drug development agreement for a SGLT2 diabetes 2 therapy with Vancouver’s Sirona Biochem. Eight years ago, Wanbang acquired China human rights to the SGLT2 candidate, then in pre-clinical studies. Now, Sirona is negotiating to sell international human and animal rights for the drug to two separate companies. Because Wanbang has developed data and manufacturing expertise for the SGLT2 product, Sirona says adding Wanbang to the deal makes the product more attractive. Wanbang stopped developing the drug after a generic SGLT2 product became available in China. More details....

Stock Symbol: (TSX-V: SBM)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital